How to Diagnose and Treat CD5-Positive Lymphomas Involving the Spleen

Curr Oncol. 2021 Nov 11;28(6):4611-4633. doi: 10.3390/curroncol28060390.

Abstract

Patients with CD5-expressing lymphomas presenting with splenomegaly are frequently diagnosed with chronic lymphocytic leukemia. The most important differential diagnosis is mantle cell lymphoma, both in its classical and leukemic, non-nodal forms, given its prognostic and therapeutic implications. Other small B-cell neoplasms that frequently involve the spleen and occasionally express CD5 include the splenic marginal zone lymphoma, hairy cell leukemia and, rarely, lymphoplasmacytic lymphoma. The frequency of CD5 positivity depends in part on the sensitivity of the detection methods employed. Usually, a combination of morphological, immunophenotypic and molecular findings allows for a precise sub-classification of CD5-positive, low-grade B-cell lymphomas of the spleen. Some of these tumors may display a mixture of small and larger B cells, raising the possibility of more aggressive lymphomas, such as diffuse large B-cell lymphomas (DLBCL). Approximately 5-10% of DLBCL are CD5-positive and some may manifest as primary splenic lesions. When available, the morphology of DLBCL in the splenic tissue is distinctive and a leukemic picture is very rare. In conclusion, the appropriate morphological and clinical context assisted by flow cytometry panels and/or immunohistochemistry allows the differential diagnosis of CD5-positive, non-Hodgkin, B-cell lymphomas involving the spleen.

Keywords: B-cell lymphoma; CD5; differential diagnosis; immunophenotype; low-grade; splenic lymphoma.

Publication types

  • Review

MeSH terms

  • Adult
  • Flow Cytometry / methods
  • Humans
  • Immunophenotyping
  • Leukemia, Lymphocytic, Chronic, B-Cell*
  • Lymphoma, Mantle-Cell*
  • Spleen / pathology